4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
Zacks
More News
IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why
Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, according to The Fly.
Stocktwits
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
Stocktwits
IOVA Flags Year-End Data Slate After Record Amtagvi Quarter, Highlights ‘Clear Line Of Sight To Profitability’
Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never the hindrance, but getting its therapy to patients.
Stocktwits
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy
Stocktwits
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
Stocktwits
Dow, S&P 500, Nasdaq Futures Mixed Ahead Of Fed Rate Decision As AI Uncertainty Mounts: IOVA, PLAY, ELMT, RBLX Stocks In Focus
The Federal Open Market Committee (FOMC) meeting is scheduled for Sept. 15–16.
Stocktwits
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Zacks
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Zacks
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.